TABLE 1.
Characteristics of osimertinib‐treated patients in this study
| Total | N = 57 |
|---|---|
| Age, median (range) | 72 (42–88) |
| Sex | |
| Female | 39 (68%) |
| Male | 18 (32%) |
| Smoking status | |
| Never smoker | 42 (74%) |
| Ex or current smoker | 15 (26%) |
| Stage | |
| Ⅲ | 9 (16%) |
| Ⅳ or recurrence | 48 (84%) |
| Extrathoracic metastasis | |
| Present | 30 (53%) |
| Absent | 27 (47%) |
| EGFR activating mutation | |
| Ex19 del | 30 (53%) |
| L858R | 27 (47%) |
| T790 M detection (cobas®) a | |
| Tissue | 44 (77%) |
| ctDNA | 16 (28%) |
| Best response to osimertinib b | |
| CR | 3 (5%) |
| PR | 30 (53%) |
| SD | 19 (33%) |
| PD | 4 (7%) |
| NE | 1 (2%) |
a
The sample for T790 M test was each clinician's choice. T790 M was detected in both tissue and ctDNA in three patients.
b
One patient was not evaluated for response to osimertinib.